Realizing the untapped potential of liquid biopsy

Optimizing patient care requires non-invasive tests for disease diagnosis, monitoring, and prognosis.

While genomic-based liquid biopsies are transforming cancer care, this method is non-applicable for population-wide screens due to high costs, and not suitable for most other diseases outside oncology

MetaSight develops and deploys accurate, affordable, and accessible diagnostics for diverse diseases through a single blood test – applicable for population scale screening.

Our approach leverages the world’s largest clinico multi-OMICS database, generated using our proprietary unbiased metabolomics, lipidomics, and proteomics platform.